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Supplementary Figure 1: Validation of 5B2 and MN-1 anti-mesothelin antibodies. (A and B), RT-PCR (A) and
immunoblot (B) analyses of pancreatic cancer and malignant pleural mesothelioma cell lines. The 21-nucleotide duplex siRNAs were synthesized as follows: siMSLN, 5′-CCCGUUUCUUCUCCCGCAUTT-3′ and 5′-AUGCGGGAGAAGAAACGGGTT-3′; siControl, 5′-GACAACGACGAAAGAUACUTT-3′ and 5′-AGUAUCUUUCGUCGUUGUCTT-3′. After 48 hours of siRNA transfection, wholecell lysate and total RNA were purified and subjected for RT-PCR and immunoblot analyses, respectively. For immunoblot analyses, the antibodies were applied at a dilution of 1:500 (5B2) and 1:40,000 (MN-1). Mesothelin precursor protein (71 kDa) and mesothelin (40 kDa) were detected in immunoblot analyses. However, MPF (megakaryocyte potentiating factor, 31 kDa) was not detected in both antibodies.
